- Home
- RSVR vs KROS Comparison
RSVR vs KROS Comparison
Compare RSVR & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RSVR | KROS |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.9M | 584.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | RSVR | KROS |
|---|---|---|
| Price | $10.20 | $11.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $11.50 | ★ $21.86 |
| AVG Volume (30 Days) | 50.3K | ★ 314.1K |
| Earning Date | 05-27-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $243,864,000.00 |
| Revenue This Year | $10.95 | N/A |
| Revenue Next Year | $4.16 | $2,751.79 |
| P/E Ratio | $77.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.97 | $9.79 |
| 52 Week High | $10.43 | $22.55 |
Technical Indicators
Market Signals| Indicator | RSVR | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 57.54 | 48.65 |
| Support Level | $9.64 | $10.64 |
| Resistance Level | $10.27 | $12.43 |
| Average True Range (ATR) | 0.24 | 0.67 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 62.68 | 58.88 |
Price Performance
Historical ComparisonAbout RSVR Reservoir Media Inc.
Reservoir Media Inc is an independent music company. It operates a music publishing business, a recorded music business, a management business, and a rights management entity in the Middle East. The company's segments include Music Publishing and Recorded Music. It generates the maximum of its revenue from the Music Publishing segment.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.